List of Zingo drug patents

Zingo is owned by Powder Pharms.

Zingo contains Lidocaine Hydrochloride.

Zingo has a total of 3 drug patents out of which 0 drug patents have expired.

Zingo was authorised for market use on 16 August, 2007.

Zingo is available in system;intradermal dosage forms.

Zingo can be used as zingo intradermal injection system is a drug delivery system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action, zingo is a powder intradermal system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action.

The generics of Zingo are possible to be released after 28 September, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8540665 POWDER PHARMS Particle cassettes and processes therefor
Oct, 2029

(6 years from now)

US9358338 POWDER PHARMS Particle cassettes and processes therefor
Apr, 2035

(12 years from now)

US9370622 POWDER PHARMS Devices and methods for delivering particles
Sep, 2035

(12 years from now)

Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 August, 2007

Treatment: Zingo intradermal injection system is a drug delivery system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action; Zingo is a powder intradermal system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action

Dosage: SYSTEM;INTRADERMAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in